新诺威(300765) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥543,456,419.92, representing a year-over-year increase of 7.18%[5] - The net profit attributable to shareholders was -¥21,302,733.89, a significant decline of 1,025.45% compared to the same period last year[5] - Total operating revenue for Q3 2025 reached CNY 1,593,014,097.66, an increase of 7.7% compared to CNY 1,478,923,011.81 in the same period last year[19] - Net profit for the period was a loss of CNY 310,248,602.63, compared to a loss of CNY 46,481,389.50 in the same quarter last year[19] - Basic and diluted earnings per share were both reported at -0.0173, compared to 0.0995 in the same quarter last year[19] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥175,121,559.93, showing an improvement of 81.67% from the previous year[11] - Operating cash flow for the current period was -175,121,559.93 CNY, an improvement from -955,575,497.94 CNY in the previous period[22] - Cash inflow from operating activities totaled 1,531,540,956.53 CNY, compared to 1,474,347,715.04 CNY in the prior year[22] - The company reported a net cash flow from investment activities of -244,872,397.40 CNY, an improvement from -918,868,799.42 CNY in the previous period[22] - The company’s cash outflow for financing activities was 54,933,251.68 CNY, down from 691,589,728.40 CNY in the previous period[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,210,880,638.20, reflecting a 3.13% increase from the end of the previous year[5] - Total liabilities increased to CNY 2,046,053,463.52, compared to CNY 1,526,185,458.97 in the previous year[18] - The equity attributable to shareholders of the parent company decreased to CNY 3,687,757,832.28 from CNY 3,730,544,275.59 year-on-year[18] - The company reported a significant increase in accounts payable, which rose to CNY 474,991,650.54 from CNY 303,326,595.53 year-on-year[18] Research and Development - Research and development expenses increased by 49.56% year-over-year, totaling ¥683,435,255.69, driven by enhanced investment in innovation[10] - Research and development expenses rose significantly to CNY 683,435,255.69, a 49.5% increase from CNY 456,957,233.20 in the previous year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,410, with the largest shareholder holding 73.83% of the shares[12] - The company plans to increase its stake in Giant Bio by acquiring 29% of its shares for a cash consideration of RMB 1.1 billion, raising its ownership from 51% to 80%[14] - The acquisition of shares is expected to create greater value for all shareholders[14] Government Support - The company received government subsidies totaling ¥4,249,218.58 during the quarter, contributing to a year-to-date total of ¥71,944,745.16[6] Strategic Focus - The company is focused on enhancing its strategic layout in the innovative biopharmaceutical sector[14] - The company's financial position reflects a strong emphasis on managing liquidity and receivables effectively[16] - The ongoing acquisition process is being conducted in an orderly manner, with further details available on the company's official announcements[14]